IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway

Molecular Immunology

Volumn 56, Issue 4, 2013, Pages 619-629

  Gong, Bing ^a   Pan, Yong ^a   Zhao, Wei ^a   Knable, Lindsay ^a   Vempati, Prashant ^a   Begum, Shimul ^a   Ho, Lap ^a   Wang, Jun ^a   Yemul, Shrishailam ^a   Barnum, Scott ^b   Bilski, Amanda ^a   Gong, Ben Y ^a   Pasinetti, Giulio M ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Cognitive function; Complement component C5a; IVIG; LTP; PCREB

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; IMMUNOGLOBULIN G; SHORT HAIRPIN RNA; AMPA RECEPTOR; AMYLOID PRECURSOR PROTEIN; CCAAT ENHANCER BINDING PROTEIN; COMPLEMENT RECEPTOR; CREB1 PROTEIN, MOUSE; IMMUNOGLOBULIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN SLICE; COGNITION; CONTROLLED STUDY; DENTATE GYRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOLOGY; IN VITRO STUDY; LONG TERM POTENTIATION; LOW DRUG DOSE; MENTAL DETERIORATION; MOUSE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPATIAL MEMORY; TRANSGENIC MOUSE; WESTERN BLOTTING; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; BRAIN; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; IMMUNOTHERAPY; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SYNAPTIC POTENTIAL;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; BRAIN; CCAAT-ENHANCER-BINDING PROTEINS; CELLS, CULTURED; COMPLEMENT C5A; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, AMPA; RECEPTORS, COMPLEMENT; SIGNAL TRANSDUCTION; SYNAPTIC POTENTIALS;

EID: 84881108511     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.06.016     Document Type: Article

References (63)

1. Alberini C.M. Transcription factors in long-term memory and synaptic plasticity. Physiological Reviews 2009, 89:121-145.
2. Arumugam T.V., Tang S.C., Lathia J.D., Cheng A., Mughal M.R., Chigurupati S., et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:14104-14109.
3. Arumugam T.V., Woodruff T.M., Lathia J.D., Selvaraj P.K., Mattson M.P., Taylor S.M. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 2009, 158:1074-1089.
4. Benard M., Gonzalez B.J., Schouft M.T., Falluel-Morel A., Vaudry D., Chan P., et al. Characterization of C3a and C5a receptors in rat cerebellar granule neurons during maturation. Neuroprotective effect of C5a against apoptotic cell death. Journal of Biological Chemistry 2004, 279:43487-43496.
5. Bito H., Deisseroth K., Tsien R.W. CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus duration-dependent switch for hippocampal gene expression. Cell 1996, 87:1203-1214.
6. Cathala L., Holderith N.B., Nusser Z., DiGregorio D.A., Cull-Candy S.G. Changes in synaptic structure underlie the developmental speeding of AMPA receptor-mediated EPSCs. Nature Neuroscience 2005, 8:1310-1318.
7. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neuroscience 1999, 2:271-276.
8. Churn S.B., Limbrick D., Sombati S., DeLorenzo R.J. Excitotoxic activation of the NMDA receptor results in inhibition of calcium/calmodulin kinase II activity in cultured hippocampal neurons. Journal of Neuroscience 1995, 15:3200-3214.
9. D'Amelio M., Cavallucci V., Middei S., Marchetti C., Pacioni S., Ferri A., et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nature Neuroscience 2011, 14:69-76.
10. Dodel R., Neff F., Noelker C., Pul R., Du Y., Bacher M., et al. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 2010, 70:513-528.
11. Dodel R., Rominger A., Bartenstein P., Barkhof F., Blennow K., Forster S., et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. The Lancet Neurology 2013, 12:233-243.
12. Doong H., Rizzo K., Fang S., Kulpa V., Weissman A.M., Kohn E.C. CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins. Journal of Biological Chemistry 2003, 278:28490-28500.
13. Farkas I., Takahashi M., Fukuda A., Yamamoto N., Akatsu H., Baranyi L., et al. Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. Journal of Immunology 2003, 170:5764-5771.
14. Fonseca M.I., Ager R.R., Chu S.H., Yazan O., Sanderson S.D., LaFerla F.M., et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. Journal of Immunology 2009, 183:1375-1383.
15. Fonseca M.I., McGuire S.O., Counts S.E., Tenner A.J. Complement activation fragment C5a receptors, CD88 and C5L2, are associated with neurofibrillary pathology. Journal of Neuroinflammation 2013, 10. doi:10.1186.
16. Gerlo S., Verdood P., Hooghe-Peters E.L., Kooijman R. Multiple, PKA-dependent and PKA-independent, signals are involved in cAMP-induced PRL expression in the eosinophilic cell line Eol-1. Cellular Signalling 2005, 17:901-909.
17. Gong B., Vitolo O.V., Trinchese F., Liu S., Shelanski M., Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. Journal of Clinical Investigation 2004, 114:1624-1634.
18. Gong B., Cao Z., Zheng P., Vitolo O.V., Liu S., Staniszewski A., et al. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006, 126:775-788.
19. Gong B., Chen F., Pan Y., Arrieta-Cruz I., Yoshida Y., Haroutunian V., et al. SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function. Aging Cell 2010, 9:1018-1031.
20. Gong B., Pan Y., Vempati P., Zhao W., Knable L., Ho L., et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiology of Aging 2013, 34:1581-1588.
21. Hopken U.E., Lu B., Gerard N.P., Gerard C. Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. Journal of Experimental Medicine 1997, 186:749-756.
22. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Ab elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-103.
23. Humeau Y., Reisel D., Johnson A.W., Borchardt T., Jensen V., Gebhardt C., et al. A pathway-specific function for different AMPA receptor subunits in amygdala long-term potentiation and fear conditioning. Journal of Neuroscience 2007, 27:10947-10956.
24. Johannessen M., Delghandi M.P., Moens U. What turns CREB on?. Cellular Signalling 2004, 16:1211-1227.
25. Konteatis Z.D., Siciliano S.J., Van Riper G., Molineaux C.J., Pandya S., Fischer P., et al. Development of C5a receptor antagonists. Differential loss of functional responses. Journal of Immunology 1994, 153:4200-4205.
26. Kumar H., Kim B.W., Song S.Y., Kim J.S., Kim I.S., Kwon Y.S., et al. Cognitive enhancing effects of alpha asarone in amnesic mice by influencing cholinergic and antioxidant defense mechanisms. Bioscience, Biotechnology, and Biochemistry 2012.
27. Lobello K., Ryan J.M., Liu E., Rippon G., Black R. Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. International Journal of Alzheimer's Disease 2012, 2012:628070.
28. Loeffler D.A. Using animal models to determine the significance of complement activation in Alzheimer's disease. Journal of Neuroinflammation 2004, 1:18.
29. Magga J., Puli L., Pihlaja R., Kanninen K., Neulamaa S., Malm T., et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. Journal of Neuroinflammation 2010, 7:90.
30. Malinow R., Malenka R.C. AMPA receptor trafficking and synaptic plasticity. Annual Review of Neuroscience 2002, 25:103-126.
31. Mao L.M., Zhang G.C., Liu X.Y., Fibuch E.E., Wang J.Q. Group I metabotropic glutamate receptor-mediated gene expression in striatal neurons. Neurochemical Research 2008, 33:1920-1924.
32. Menniti F.S., Faraci W.S., Schmidt C.J. Phosphodiesterases in the CNS: targets for drug development. Nature Reviews Drug Discovery 2006, 5:660-670.
33. Mollnes T.E. Complement and biocompatibility. Vox Sanguinis 1998, 74(Suppl. 2):303-307.
34. Mukherjee P., Pasinetti G.M. The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. Journal of Neuroimmunology 2000, 105:124-130.
35. Mukherjee P., Pasinetti G.M. Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. Journal of Neurochemistry 2001, 77:43-49.
36. Mukherjee P., Thomas S., Pasinetti G.M. Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. Journal of Neuroinflammation 2008, 5:5.
37. Nayak A., Zastrow D.J., Lickteig R., Zahniser N.R., Browning M.D. Maintenance of late-phase LTP is accompanied by PKA-dependent increase in AMPA receptor synthesis. Nature 1998, 394:680-683.
38. Ninan I., Arancio O. Presynaptic CaMKII is necessary for synaptic plasticity in cultured hippocampal neurons. Neuron 2004, 42:129-141.
39. O'Barr S.A., Caguioa J., Gruol D., Perkins G., Ember J.A., Hugli T., et al. Neuronal expression of a functional receptor for the C5a complement activation fragment. Journal of Immunology 2001, 166:4154-4162.
40. Osaka H., Mukherjee P., Aisen P.S., Pasinetti G.M. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. Journal of Cellular Biochemistry 1999, 73:303-311.
41. Otto M., Hawlisch H., Monk P.N., Muller M., Klos A., Karp C.L., et al. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. Journal of Biological Chemistry 2004, 279:142-151.
42. Perianayagam M.C., Balakrishnan V.S., Pereira B.J., Jaber B.L. C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and Bad-mediated signalling pathway. European Journal of Clinical Investigation 2004, 34:50-56.
43. Perianayagam M.C., Madias N.E., Pereira B.J., Jaber B.L. CREB transcription factor modulates Bcl2 transcription in response to C5a in HL-60-derived neutrophils. European Journal of Clinical Investigation 2006, 36:353-361.
44. Plant K., Pelkey K.A., Bortolotto Z.A., Morita D., Terashima A., McBain C.J., et al. Transient incorporation of native GluR2-lacking AMPA receptors during hippocampal long-term potentiation. Nature Neuroscience 2006, 9:602-604.
45. Ramaglia V., Daha M.R., Baas F. The complement system in the peripheral nerve: friend or foe?. Molecular Immunology 2008, 45:3865-3877.
46. Reiman R., Campos Torres A., Martin B.K., Ting J.P., Campbell I.L., Barnum S.R. Expression of C5a in the brain does not exacerbate experimental autoimmune encephalomyelitis. Neuroscience Letters 2005, 390:134-138.
47. Rothermel E., Zwirner J., Vogt T., Rabini S., Gotze O. Molecular cloning and expression of the functional rat C5a receptor. Molecular Immunology 1997, 34:877-886.
48. Rus H., Cudrici C., Niculescu F., Shin M.L. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. Journal of Neuroimmunology 2006, 180:9-16.
49. Sarter M., Bodewitz G., Stephens D.N. Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology 1988, 94:491-495.
50. Savva G.M., Wharton S.B., Ince P.G., Forster G., Matthews F.E., Brayne C., et al. Age, neuropathology, and dementia. New England Journal of Medicine 2009, 360:2302-2309.
51. Sayah S., Jauneau A.C., Patte C., Tonon M.C., Vaudry H., Fontaine M. Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes. Brain Research. Molecular Brain Research 2003, 112:53-60.
52. Schmitt J.M., Guire E.S., Saneyoshi T., Soderling T.R. Calmodulin-dependent kinase kinase/calmodulin kinase I activity gates extracellular-regulated kinase-dependent long-term potentiation. Journal of Neuroscience 2005, 25:1281-1290.
53. Shayan G., Adamiak B., Relkin N.R., Lee K.H. Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy. Electrophoresis 2012, 33:1975-1979.
54. Stevens C.F. CREB and memory consolidation. Neuron 1994, 13:769-770.
55. Stevens B., Allen N.J., Vazquez L.E., Howell G.R., Christopherson K.S., Nouri N., et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007, 131:1164-1178.
56. Szabo P., Relkin N., Weksler M.E. Natural human antibodies to amyloid beta peptide. Autoimmunity Reviews 2008, 7:415-420.
57. Thomas G.M., Huganir R.L. MAPK cascade signalling and synaptic plasticity. Nature Reviews Neuroscience 2004, 5:173-183.
58. Turner M.W. 90 years on: a therapy to 'stimulate the phagocytes'?. Scandinavian Journal of Immunology 1998, 48:124-126.
59. van Beek J., Nicole O., Ali C., Ischenko A., MacKenzie E.T., Buisson A., et al. Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport 2001, 12:289-293.
60. Wayman G.A., Impey S., Marks D., Saneyoshi T., Grant W.F., Derkach V., et al. Activity-dependent dendritic arborization mediated by CaM-kinase I activation and enhanced CREB-dependent transcription of Wnt-2. Neuron 2006, 50:897-909.
61. Wozniak M.A., Itzhaki R.F. Intravenous immunoglobulin reduces beta amyloid and abnormal tau formation caused by herpes simplex virus type 1. Journal of Neuroimmunology 2013, 257:7-12.
62. Wu G.Y., Cline H.T. Stabilization of dendritic arbor structure in vivo by CaMKII. Science 1998, 279:222-226.
63. Yanamadala V., Friedlander R.M. Complement in neuroprotection and neurodegeneration. Trends in Molecular Medicine 2010, 16:69-76.